Chemotherapy in patients with metastatic or relapsed germ-cell tumours

Cancer Treatment Reviews

Volumn 27, Issue 5, 2001, Pages 283-288

  Rick, O ^a   Siegert, W ^a   Beyer, J ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL; THIOTEPA; VINBLASTINE;

ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; GERM CELL TUMOR; HUMAN; MEDICAL DECISION MAKING; METASTASIS; MULTICENTER STUDY; PREDICTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SALVAGE THERAPY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035159772     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0230     Document Type: Article

References (32)

1. Testicular germ-cell cancer
2. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers
3. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide
4. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis
5. Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer
6. Treatment of testicular cancer: A new and improved model
7. Prognostic factors for favorable outcome in disseminated germ cell tumors
8. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy
9. Intensive induction sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic non-seminomatous germ cell tumor: A randomized Medical Research Council/European Organisation and Treatment of Cancer study
10. Experience with bleomycin, etoposide, cisplatin (BEP) an alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II)/vinblastine, bleomycine (VB (IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors
11. Four cycles of BEP versus an alternating regimen and PVB and PEB in patients with poor prognosis metastatic testicular non-seminoma: A randomized study of the EORTC-Genitourinary Tract Cancer Cooperative Group
12. Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastin or etoposid
13. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminmatous germ cell tumours: Preliminary results of a French randomized trial
14. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors
15. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors
16. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer
17. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: Results of a multicentre study
18. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from an EORTC multiinstitutional phase III study
19. Prognostic factors in advanced nonseminomatous testicular cancer
20. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicentre experience
21. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
22. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer
23. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients
24. Treatment intensification in disseminated germ-cell tumors
25. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma
26. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor
27. High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany
28. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission
29. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic factors
30. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience
31. Prognostic factors in patients progressing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours
32. Amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor